Biochemical Pharmacology xxx (2009) xxx-xxx



1

2

3

4

5

6 7 Contents lists available at ScienceDirect

Biochemical Pharmacology



journal homepage: www.elsevier.com/locate/biochempharm

Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel

Jerzy Karczewski^{a,1,*}, Jixin Wang^{a,1}, Stefanie A. Kane^a, Laszlo Kiss^a, Kenneth S. Koblan^a, QIJ. Christopher Culberson^b, Robert H. Spencer^{a,2}

^a Department of Pain Research, Merck Research Laboratories, West Point, PA, United States ^b Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, United States

ARTICLE INFO

Article history: Received 28 December 2008 Accepted 17 February 2009 Available online xxx

Keywords: hERG potassium channel MK-499 lon channel pharmacology Site-directed mutagenesis Molecular modeling

1. Introduction

ABSTRACT

Drug-induced long QT syndrome has been principally ascribed to block of the cardiac hERG K⁺ channel. Methanesulfonanilides, such as MK-499, E-4031 and dofetilide, are potent hERG antagonists that likely bind along the S6 helix within the inner vestibule of the pore. To further investigate these interactions, we broadly explored the structure-activity relationships of closely related analogs of MK-499 using a high-throughput ion flux assay, and evaluated in greater detail using patch-clamp electrophysiology. We observed that substitutions at the 4-position on the benzopyran ring significantly affected the potency of these analogs with the rank order of unsubstituted \approx ketone > amine > hydroxyl, implicating an important interaction at this position. We also evaluated the potency of these analogs on an S6 mutant of hERG (F656A) previously shown to significantly reduce the affinity for MK-499 and other known hERG antagonists (e.g. cisapride, terfenadine). In contrast to MK-499 (4-hydroxyl) and either the amine or unsubstituted analogs, the potency of the ketone analog was unaffected by this mutation suggesting that a compensatory interaction may be unveiled with the aromatic to apolar substitution, possibly through hydrogen bonding with Ser624 based on molecular modeling. More significantly, we found that this mutation rendered hERG susceptible to block in the closed-state by the smaller, unsubstituted analog, but not by MK-499 or larger analogs. Together these data suggest that interaction with Phe656 is not an absolute requirement for the binding of all methanesulfonanilide compounds, and that this residue may play a broader role in regulating access to the inner vestibule.

© 2009 Published by Elsevier Inc.

9 10

10 11

12

13

14

15

16

17

18

Since the identification of the *HERG*¹ gene (KCNH2), which encodes a rapidly inactivating delayed-rectifier K⁺ channel α subunit, as the molecular entity underlying the *I*_{Kr} current in human heart [1,2], a vast amount of information has implicated this channel in both congenital and acquired forms of long QT syndrome (LQTS)—a disorder associated with an increased risk for ventricular tachyarrhythmia (torsade de pointes) that can degenerate into ventricular fibrillation and sudden death [3]. Although

0006-2952/\$ – see front matter © 2009 Published by Elsevier Inc. doi:10.1016/j.bcp.2009.02.011

hERG is expressed in a variety of tissues [4], its critical functional 19 role in the repolarization phase of the cardiac action potential, in 20 21 addition to I_{Ks} (KvLQT1), has provided the impetus for a detailed understanding of the structure and function of this channel. 22 Inherited mutations which alter either the function or level of 23 expression of hERG (KCNH2) have been linked to a form of LQTS 24 known as LOT2 [3,5]. Acquired, or drug-induced, LOTS has been 25 primarily, if not exclusively, associated with compounds which can 26 block hERG. These include several Class III antiarrhythmics (e.g. 27 dofetilide, sotalol) as well as a plethora of structurally distinct 28 drugs encompassing antihistamines, antimicrobials, GI prokinetic 29 and psychotropic agents (reviewed in [6]). 30

Significant advances have been made in the identification of 31 residues within the pore of hERG responsible for the binding of 32 these drugs with the intention of developing a pharmacophore 33 model that could be applied for reducing or eliminating the 34 potential for drug-induced QT prolongation [7,8]. In this study, we 35 have utilized a high-throughput Rb^+ efflux assay together with 36 whole-cell patch-clamp analysis to develop a refined model for 37

^{*} Corresponding author at: Merck Research Laboratories, WP26A-2000, P.O. Box 4, West Point, PA 19486, United States. Tel.: +1 215 652 3505; fax: +1 215 652 0800.

E-mail address: jerzy_karczewski@merck.com (J. Karczewski).

¹ Both authors contributed equally to this work.

² Current address: Cara Therapeutics, Inc., Shelton, CT 06484, USA.

Abbreviations: AAS, atomic absorption spectrometry; *HERG*, human ether-a-go-go related gene (KCNH2); hERG, ether-a-go-go-related potassium channel protein; Kv, voltage-gated K⁺ channel; LQTS, long QT syndrome; CHO, Chinese hamster ovary.

38 drug interactions within hERG. Rather than broadly investigating 39 the activities for a variety of structurally unrelated chemotypes on 40 a series of hERG mutants, we chose to study a series of close 41 analogs of the well-characterized hERG antagonist MK-499 on the 42 wild-type channel, and on a single site mutation (F656A) 43 previously reported to dramatically affect the potency of this 44 and several other hERG blockers. This choice allowed us to probe 45 the details of molecular interactions between this inhibitor and the 46 hERG channel in a limited structural series. It is anticipated that the 47 observed interactions will provide insights that are pertinent not 48 only to methanesulfonanilide antagonists but also to compounds 49 from other structural classes.

50 2. Materials and methods

2.1. Materials 51

52 MK-499, all structurally related analogs, and sertindole, were 53 synthesized in the Department of Medicinal Chemistry at Merck 54 Research Laboratories Cisapride, astemizole and all other chemi-55 cals were obtained from Sigma Aldrich Corp. (St. Louis, MO, USA).

56 2.2. Molecular biology

57 The hERG/pSP64 construct was provided by Sanguinetti et al. 58 [2]. hERG was cloned into pCDNA5/FRT vector between HindIII an 59 BamHI and used to generate a stable CHO cell line. To generate the 60 F656A point mutation in hERG, site-directed mutagenesis was performed using methylated hERG/pSP64 according to the 61 62 GeneTailor method (Invitrogen, Carlsbad, CA, USA). After ampli-63 fication, mutated unmethylated product was selected in DH5 α E. coli cells. The 176 bp cassette between BglII and XhoI containing 64 the target site was swapped into WT hERG/pCDNA5/FRT. WT and 65 F656A hERG constructs were confirmed by restriction mapping 66 67 and DNA sequencing.

68 2.3. Expression of hERG and F656A mutant in Flp-In CHO cells

69 hERG and the F656A mutant were expressed in CHO cells 70 using the Flp-In system (Invitrogen). Flp-In host CHO cells 71 containing a single integrated Flp Recombination Target (FRT) 72 site were cotransfected using Lipofectamine 2000 (Invitrogen). 73 For each transfection, 0.4 µg hERG/pCDNA5/FRT (or F656A 74 hERG/pCDNA5/FRT) and 3.6 µg pOG44 (for expression of the 75 Flp recombinase) were incubated with Flp-In CHO cells for 5 h in 76 Opti-MEM I serum-free medium (Invitrogen). The stable expression cell line was selected by culturing cells in the 77 78 presence of 200 µg/ml hygromycin. The cells were maintained 79 in F-12 medium containing 10% FBS, 100 U/ml penicillin, 80 100 µg/ml streptomycin, 200 µg/ml hygromycin at 37 °C with 81 5% CO₂. The expression of hERG or F656A hERG was confirmed 82 by Western Blot analysis using anti-hERG antibody (Alomone 83 Labs. Ltd., Jerusalem, Israel).

84 2.4. Rubidium efflux assay

85 CHO cells were seeded in 96-well V-bottom microtiter plates at 86 4×10^4 cells per well and allowed to grow for 48 h. The medium 87 was then aspirated, Rb-Load Buffer (Aurora Biomed, Vancouver, 88 Canada) containing 5.4 mM RbCl was added, and cells were incubated at 37 °C for 3 h to obtain maximal loading [9]. The Rb-89 90 Load Buffer was washed off the cells with $5 \times 200 \,\mu$ l/well of 91 Hanks' Balanced Salt Solution (HBSS). Drugs were dissolved in 92 DMSO at 10 mM concentration, serially diluted into 100 µl HBSS, 93 and added to cells for 10 min. The cells were subsequently 94 depolarized by the addition of 100 μ l/well of 2× depolarization buffer (HBSS modified by the replacement of 100 mM NaCl with 95 100 mM KCl). After 10 min incubation at room temperature, the 96 supernatant was transferred into a clean 96-well plate and cell 97 lysis buffer (200 μ l/well) was added to the assay plate to release 98 99 intracellular Rb⁺ (Aurora Biomed, Vancouver, Canada). All liquid handling was performed using a Biomek FX Laboratory Workstation (Beckman Coulter Inc., Fullerton, CA, USA).

The Rb⁺ concentration was measured in both the supernatant and the cell lysate (100 µl sample of each) using an automated atomic 104 absorption spectrophotometer (Model: ICR-8000; Aurora Biomed, Vancouver, Canada). Rb⁺ efflux was calculated using Equation I: %efflux = $100 \times (Rb_{sup}^+ / (Rb_{sup}^+ + Rb_{lvs}^+))$. In order to quantify the effect of drugs, the data was converted into %inhibition calculated 107 using Equation II: %inhibition = $100 - ((efflux_{drug} - efflux_{min})/$ (efflux_{max} – efflux_{min})), where efflux_{drug} is the Rb^+ efflux in the 109 presence of tested drug, efflux_{min} is the Rb⁺ efflux in the presence of 110 10 μ M astemizole, efflux_{max} is the Rb⁺ efflux in the presence of 0.25% 111 DMSO. Nonlinear regression analysis was used to calculate the IC_{50} 112 values using the program Prism (GraphPad Software, San Diego, CA). 113

Due to the low level of functional expression (i.e. low signal-to-114 noise) we initially observed for the F656A mutant in CHO cells and 115 also reported for its expression in Xenopus oocytes [8], cells were 116 preincubated at 30 °C for 48 h which increased the current density 117 by \sim 55%, as verified by patch-clamp analysis (data not shown). The 118 use of low temperature or chemical chaperones to facilitate surface 119 expression of hERG mutants, as well as other membrane proteins, 120 has been reported [10–12]. 121

2.5. Voltage-clamp recordings

Cells for electrophysiological study were transferred to an 80 µl 123 124 RC-24 recording chamber (Warner Instrument Corp., Hamden, CT, 125 USA) and superfused with a Hank's Balanced Salt Solution (Invitrogen) containing (mM): 137.97 NaCl, 1.26 CaCl₂, 0.49 126 MgCl₂, 0.41 MgSO₄, 5.33 KCl, 0.44 KH₂PO₄, 4.17 NaHCO₃, 0.34 127 Na₂HPO₄, 5.56 D-glucose, pH 7.3, at a flow rate of 0.8 ml/min, 128 allowing rapid solution changes. K⁺ currents were recorded using 129 the whole-cell patch-clamp technique at room temperature 130 $(23 \pm 1^{\circ} \text{ C})$. An Axopatch 200A patch-clamp amplifier was connected 131 through a Digidata 1200 interface (Molecular Devices, Sunnyvale, CA, 132 USA). Patch pipettes were fabricated from capillary glass tubing 133 obtained from Warner Instrument Corp. $(1.16-1.5 \times 750 \text{ mm})$; 134 #G85150T-3) using a vertical micropipette puller (L/M-3p-A, LIST-135 MEDICAL, Darmstadt, Germany). Pipette resistances were 2–4 M Ω 136 when filled with a solution containing (mM): 119 K⁺-gluconate, 15 137 KCl, 3.2 MgCl₂, 5 EGTA, 5 K₂ATP, 5 HEPES, pH 7.35. Cell capacitance 138 and series resistance were compensated (80-90%) before recording. 139 140 Data were acquired and analyzed using pCLAMP9 (Molecular Devices) and results were plotted using SigmaPlot (Systat Software, 141 Chicago, IL, USA). 142

2.6. Molecular modeling

The 1BL8 KcsA structure was retrieved from the Protein Data 144 Bank. The KcsA structure was used as the template structure for a 145 homology model created by using the MODELER module within 146 INSIGHTII (Ver. 98.0; Accelrys, San Diego, CA, USA). The sequence 147 alignment from Doyle et al. [13] was used to generate the 148 homology model. Subsequent molecular modeling was done with 149 the Merck molecular modeling system (MIX). One hundred low-150 energy conformations of MK-499 were generated and docked by 151 using the FLOG (Flexible Ligands Oriented on Grid) procedure [14]. 152 Subsequently the docked conformations were energy minimized 153 with macromodel using the MMFF force field [15] while allowing 154 the side chains within 10 Å of the ligand to flex while holding the 155 backbone rigid [16]. 156

Please cite this article in press as: Karczewski J, et al. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel. Biochem Pharmacol (2009), doi:10.1016/j.bcp.2009.02.011

2

102 103

100

101

105 106

108

122

143

157 3. Results

(A) 100

Rb⁺ Efflux (%)

80

60

40

20

(B) 110

% INHIBITION

90

70

50

30

10

-10

-9

0 20 40

60 80

-7

[Compound] (Log M)

-8

[KCI] (mM)

158 3.1. Initial characterization of hERG antagonists using atomic159 absorption spectrometry

160 Due to the unique functional properties of ion channels, the 161 rapid evaluation of compounds that modulate their function has posed a difficult challenge. In order to investigate the structure-162 activity relationships for a broad series of chemical entities against 163 164 hERG, we utilized a non-radioactive ion flux assay using atomic 165 absorption spectrometry (AAS) which has shown utility for rapidly 166 evaluating the pharmacological properties of several voltage- and 167 ligand-gated ion channels [17].

168 The application of AAS for determining the pharmacology of the 169 hERG K⁺ channel has been reported and involves loading the cells 170 with nonradioactive Rb⁺ and measuring the potency of antagonists 171 by the inhibition of Rb⁺ efflux upon membrane depolarization with 172 high extracellular K⁺ [18]. To optimize the conditions for this assay, 173 CHO cells expressing hERG were loaded with RbCl, washed with 174 Hank's buffer to remove the extracellular Rb⁺, and then depolarized 175 by the addition of increasing concentrations of KCl (equimolar 176 substitution for NaCl)(Fig. 1A). Rb⁺ efflux was then measured in the 177 supernatant and cell lysate using an automated atomic absorption 178 spectrophotometer (see Section 2). Maximal efflux of Rb⁺ from CHO-179 hERG cells was attained with 50 mM KCl, and no further increase 180 was observed with concentrations up to 140 mM ($EC_{50} = 22 \text{ mM}$ 181 KCl). To ensure that the kinetic endpoint for efflux was being 182 attained, the Rb⁺ concentration was measured in the supernatant 183 from cells depolarized for varying lengths of time, and maximal

CHO-hERG

CHO control

astemizole

Cisapride MK-499

Sertindole

-5

100 120 140 160

CHO-hERG +10µM Astemizole

efflux was observed after 10 min (data not shown). The addition of 184 10 μ M astemizole, a potent inhibitor of hERG, completely blocked 185 the efflux of Rb⁺ demonstrating that ion permeation was specific to 186 the heterologously expressed hERG channel. Minimal Rb⁺ efflux was 0bserved in untransfected CHO cells, consistent with the lack of 188 native outward K⁺ conductance in these cells [19,20]. 189

190 To evaluate the pharmacology of hERG in this assay, the doseresponse relationship for several known antagonists was deter-191 mined using these methods (Fig. 1B). The IC₅₀ values for these 192 compounds as measured with this assay are somewhat higher than 193 values reported using single-cell patch-clamp analysis, but they 194 are consistent with the known pharmacology of hERG and with 195 values reported using other functional, high-throughput techni-196 ques [18,21,22]. Although some of these compounds display 197 positive voltage-dependent block which cannot be readily 198 investigated by AAS due to technical limitations (i.e. the membrane 199 cannot depolarize to positive potentials) [23–25], general structure 200 -activity relationships were readily identified and informative for 201 more definitive analysis by patch-clamp electrophysiology. 202

3.2. Substituents on pyran ring influence potency of MK-499 analogs on hERG

To characterize the structure–activity relationships for a 205 series of MK-499 analogs, we determined their relative potency 206




Fig. 1. Analysis of Rb⁺ efflux for the hERG channel expressed in CHO cells and dosedependent inhibition using known blockers. (A) Increasing concentrations of KCI were used to depolarize the cell membrane and initiate Rb⁺ efflux from cells expressing the hERG channel. The Rb⁺ concentration in the supernatant and lysate was measured by automated atomic absorption spectrometry (AAS) and the percent efflux calculated as described in Section 2. Untransfected CHO K1 cells were used as a negative control. Astemizole (10 μ M) was used as a positive control to determine full block in CHO-hERG cells. (B) A series of known hERG antagonists were preincubated with CHO-hERG cells at increasing concentrations for 10 min. prior to activation with 50 mM KCl. Rb⁺ efflux was determined using AAS and the percent inhibition was calculated as described in Section 2. The observed IC₅₀ values were 53 (±4.8) nM, 67 (±4.9) nM, 107 (±5.7) nM, and 355 (±16.7) nM for astemizole, cisapride, MK-499 and sertindole, respectively (n = 3-6).

-6

Fig. 2. Effect of R-group substitutions on the potency of analogs of MK-499 on WT hERG and the F656A mutant using the AAS Rb⁺ efflux assay. (A) The potency of stereoisomers of MK-499 (hydroxyl) as well as amine, ketone and unsubstituted analogs on the R-4 position of the pyran ring (see inset) were determined on WT hERG. The relative potency of these structural analogs compared to that for MK-499 is plotted on a log scale (mean \pm SEM). (B) The potency of the same structural analogs of MK-499 was evaluated on the F656A mutant hERG channel. The relative effect of this mutation on the potency of these analogs is shown relative to their activity on WT hERG (mean \pm SEM).

3

203

204

J. Karczewski et al. / Biochemical Pharmacology xxx (2009) xxx-xxx

207 against the wild-type hERG channel using AAS. From these 208 results, we observed significant effects on compound potency 209 due to substitutions at the 4-position on the pyran ring (Fig. 2A). 210 In comparison to MK-499 which has a hydroxyl at this position, 211 unsubstituted or ketone-substituted analogs were 4-35-fold 212 more potent (average IC₅₀ values, 3 and 26 nM, respectively) 213 against hERG. This result is consistent with a previous study that 214 found a ketone analog of MK-499 (L-702,958) had greater 215 potency for block of the native IKr current in guinea pig 216 ventricular myocytes [IC50 values for MK-499 and L-702,958, 217 43.9 and 14.6 nM, respectively] [26]. In contrast to the increased potency observed with the ketone or unsubstituted analogs. 218 219 amine substitutions at this position were essentially equipotent 220 to MK-499 and other hydroxyl analogs.

221 3.3. Differential sensitivity of MK-499 analogs to the F656A mutation 222 in hERG

223 To further explore the binding site for MK-499, we evaluated

224 these same analogs with a single-site alanine mutation at position

225 F656 in the S6 domain of hERG. This mutation has been shown to

have the greatest effect on the potency of MK-499 in *Xenopus* oocyte voltage-clamp studies, suggesting a critical requirement for contacts between MK-499 and this aromatic side chain [8]. Additionally, the potencies of dofetilide, a related methanesulfonanilide, and quinidine were reduced by 120-fold and 25-fold, respectively, when F656 was mutated to valine [27], suggesting that small hydrophobic groups are not sufficient replacements for this residue.

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

Consistent with these data, we observed a significant reduction in the potency for MK-499 and related stereoisomers against the hERG F656A mutant in the AAS assay (Fig. 2B). The potency of amine and unsubstituted analogs of MK-499 were also significantly less potent on the F656A mutant channel with a >10-fold decrease in the IC₅₀ compared to wild-type hERG. However, quite surprisingly, we observed that ketone analogs of MK-499, such as L-702,958, were nearly equipotent on the wild-type and F656A mutant channels. This suggested that F656 may not be obligatory for the binding of all methanesulfonanilide compounds. These findings were then used to guide studies using classical patch-clamp analysis to further investigate these interactions.

Table 1

 $\mathrm{Q2}_{\mathrm{IC}_{50}}$ values for block of WT and F656A hERG channels by MK-499 and structural analogs.

		R-group	IC ₅₀ (Nm)		Relative potency
			WT	F656A	(IC ₅₀ F656A/IC ₅₀ WT)
MK-499 (R,R)		Hydroxyl	89.8 ± 9.7	2057 ± 271	22.9
Compound 2 (S,S)	O, S, O O O N H OH H OH H OH H OH H OH H OH	Hydroxyl	107 ± 19.6	1705 ± 174	15.9
Compound 3	NH2 S O O O O N	Amine	29.2 ± 7.0	356 ± 43	11.5
Compound 4	S, N, C, C, N, C, C, N, C, C, N,	Unsubstituted	5.0 ± 0.7	211 ± 27	42.2
L-702,958		Ketone	14.3 ± 1.1	29.2 ± 2.9	2.0

Steady-state block was determined from tail currents elicited by depolarization from the holding potential of -90 to 0 mV for 5 s, followed by hyperpolarization to -140 mV for 256 ms. The IC₅₀ values indicated represent the average IC₅₀ ± SEM from individual cells at each dose (n = 2-6).

J. Karczewski et al./Biochemical Pharmacology xxx (2009) xxx-xxx

247 3.4. Electrophysiological evaluation of the potency of MK-499 analogs
248 on WT and F656A hERG channels currents

249 Based upon the initial structure-activity relationships identi-250 fied using AAS, we evaluated the potency of MK-499, its 251 enantiomer (Compound 2), and three analogs containing either 252 an amine, dihydrogen (unsubstituted), or ketone at the 4-pyran 253 position. Consistent with the results from AAS, the unsubstituted 254 and ketone analogs of MK-499 were more potent than MK-499, its 255 enantiomer, or the amine analog (Compound 3) on the WT hERG 256 channel (see Table 1).

257 We then examined the effect of the F656A mutation on the 258 potency of these same compounds. Although readily measurable, 259 currents for the F656A mutant channel stably expressed in CHO 260 cells were significantly lower compared to the WT channel (see 261 Fig. 3), as has been previously reported [8,28]. Consistent with 262 results from the AAS assay, MK-499, its enantiomer, and the amine 263 and unsubstituted analogs showed a significant right-shift in their 264 IC₅₀ values compared to the WT hERG channel (Table 1), confirming previous reports that binding interactions with F656265are critical for hERG block. However, currents for the F656A mutant266were blocked with nearly equal potency by the ketone analog (L-267702,958), similar to our results using the AAS assay (Fig. 3). This268suggested that the keto oxygen of L-702,958 may be participating269in a unique binding interaction within the hERG pore that270distinguishes it from MK-499 and other analogs.271

3.5. Docking model identifies potential hydrogen bonding interactions 272 with S624 273

In order to understand these results from a structural 274 perspective, we explored docking studies of MK-499, the hydroxyl 275 enantiomer (Compound 2), and the other analogs (Compound 3, 276 Compound 4, and L-702,958) into the homology model of the 277 hERG channel previously described by Mitcheson et al. [8]. Initial 278 dockings of MK-499 analogs were done with a homology model 279 based on the KcsA crystal structure. A second round of docking 280 experiments were done using a model based on an MthK template 281




Fig. 3. The potency of structural analogs of MK-499 on hERG currents is differentially affected by the F656A mutation. Whole-cell recording of tail currents from WT and F656A hERG channels elicited by depolarization from the holding potential of -90 to 0 mV for 5 s, followed by hyperpolarization to -140 mV for 256 ms. (A) Steady-state block by MK-499 was evaluated on the WT and F656A hERG channels. (B) Steady-state block by the ketone analog (L-702,958) on WT and F656A hERG channels. Recovery from block is also shown for the same cells by measuring the tail currents after 30 pulses following washout of the maximal drug concentration tested.

6

ARTICLE IN PRESS

J. Karczewski et al./Biochemical Pharmacology xxx (2009) xxx-xxx




Fig. 4. Docking of MK-499 and ketone analog in the pore of hERG using a homology model. (A) Stereoview of the S5-S6 domain of the hERG channel with MK-499 (space-filling model) docked within the pore region. Sidechains for S624, Y652 and F656 are also shown. (B) Close-up view of the energy minimized structure of MK-499 docked within the pore of the wild-type (cyan) and the F656A mutant (green) channels. Sidechain atoms for residue 656 in the wild-type (yellow) and the F656A mutant (red) are also shown as CPK models. The closest approach heavy atom-to-heavy atom distance (3.4 Å) between S624 and MK-499 is indicated. (C) Docked and energy minimized structures of the ketone analog, L-702,958, in the wild-type (cyan) and the F656A (green) mutant channel. The heavy atom-to-heavy atom distance (3.0 Å) between S624 and L-702,958 is indicated.

J. Karczewski et al./Biochemical Pharmacology xxx (2009) xxx-xxx




Fig. 5. Block of the WT hERG channel in the inactivated state by MK-499. The WT hERG channel was forced into the inactivated state by holding the membrane potential at +100 mV for 20 s, followed by a rapid hyperpolarization step to –140 mV for 256 ms to elicit an inward tail current. (A) Tail current from WT hERG after holding the channel in the inactivated state (at +100 mV) in the absence of drug. (B) Addition of 10 μM MK-499 to the holding current of WT hERG channel while held in the inactivated state at +100 mV for 1 min (leak conductance was not subtracted). (C) Tail current elicited during the first pulse from the WT hERG channel in the presence of 10 μM MK-499 added while holding the channel in the inactivated state (+100 mV).

282 (model of the open channel state), but the conclusions from either 283 model are similar. From this study, we identified a key hydrogen 284 bonding (H-bond) interaction between S624 and the hydroxyl 285 group of MK-499, and its enantiomer. Although a modest energetic contribution was initially observed for S624 and the 286 binding of MK-499 [8], it is too long range (3.4 Å, hydroxyl oxygen 287 288 to S624 sidechain) to be considered a classical H-bond, and thus 289 likely contributes minimally to its total binding energy (Fig. 4A 290 and B).

To further extend these observations, we also performed a 291 292 docking analysis with the F656A mutant channel. These results 293 suggested that replacement of F656 with alanine would cause MK-294 499 and Compound 2 to move deeper into the pore to gain 295 interactions along S6, thereby losing any weak contact with S624. 296 However, the ketone analog (L-702,958) retained the hydrogen 297 bond to S624 in both the native and mutant channels (Fig. 4C). This 298 model thus provides a structural hypothesis consistent with the 299 functional results obtained with the MK-499 analogs for both the 300 native and mutant hERG channels.

301 3.6. Block of hERG by MK-499 in the open-inactivated state

302 The relative position of F656 along the S6 helix of hERG (likely 303 near the apex of the inverted teepee) suggests that this residue 304 may not only play a role in drug binding, but also in drug access to 305 the inner pore of the channel. Previous studies have shown that 306 methanesulfonanilides such as MK-499 and dofetilide block hERG 307 in the open state, and that drug-trapping during inactivation likely 308 explains the slow recovery from block [29]. The interaction of 309 propafenone with F656 is also regulated by the transition from the 310 closed to open state [30]. This may be due to conformational changes required for accessibility of drug to the pore and/or to 311 312 residues involved in high-affinity drug interactions. It has also 313 been shown that hERG remains susceptible to block by MK-499 314 following removal of C-type inactivation, suggesting that the pore 315 may become accessible to drug upon membrane depolarization 316 due to conformational changes associated with movement of the 317 S4 voltage-sensor with concomitant rearrangements of the S6 318 helices.

To further explore this question, we investigated whether MK-319 499 could block the WT hERG channel in the fully inactivated state. 320 By holding the membrane at a strongly depolarized potential the 321 flow of K⁺ ions would be blocked due to C-type inactivation, but the 322 voltage-sensor would remain in the activated state. To force hERG 323 into the inactivated state, the membrane was held at +100 mV for 324 20 s prior to the addition of MK-499 for an additional 60 s (Fig. 5). In 325 the absence of drug, a large inward current was elicited following a 326 rapid hyperpolarizing step to -140 mV. However, nearly complete 327 block was observed with the addition of 10 µM MK-499, suggesting 328 329 that the drug could access the inner pore following conformational changes associated with activation gating. 330


3.7. Closed channel block of F656A mutant by an MK-499 analog 331

Although hERG is blocked in the open and inactivated states 332 from the intracellular side of the channel, it does not appear to be 333 blocked in the closed state by methanesulfonanilide compounds 334 like MK-499, dofetilide and E-4031 [31,32]. Accessibility of the 335 pore to these drugs is likely restricted by a physical barrier near the 336 intracellular side of S6. To address whether F656 may play some 337 role in regulating access to the pore, we compared the ability of 338 MK-499 and the smaller, unsubstituted analog (Compound 4) to 339 block the WT and F656A hERG channel in the closed state. Similar 340 to previous studies, there was little or no accumulation of closed-341 channel block by MK-499 in either the WT or F656A mutant 342 channels (Fig. 6A and B). There was also no closed-channel block of 343 the WT hERG observed using Compound 4 (Fig. 6B). However, in 344 contrast to MK-499, significant closed-channel block of the F656A 345 mutant channel (>50% at 1μ M) was seen with Compound 4 346 (Fig. 6A). The ketone analog, L-702,958, was also unable to block 347 the closed state of F656A hERG (data not shown). This result clearly 348 indicates that Compound 4 can gain access to pore with the 349 substitution of the bulky phenylalanine residue for alanine at 350 position 656. 351

Since Compound 4 is ~ 0.8 Å narrower than MK-499 or L-702,958 (all are of equal length), this suggests that F656 likely acts as a physical barrier to restrict access to the pore in the closed state (Fig. 6C). It also suggests that F656 is located at or near the 355

8

J. Karczewski et al. / Biochemical Pharmacology xxx (2009) xxx-xxx






Fig. 6. Closed-channel block of the F656A hERG channel by the small, unsubstituted analog of MK-499. Block of WT and F656A hERG in the closed state was evaluated by holding the channel closed at -90 mV while washing on the drug for 5 min, followed by a brief activation step for 50 ms at +100 mV prior to stepping to -140 mV for 256 ms to quantify the hERG tail current. (A) Evaluation of closed-channel block for the F656A hERG channel by MK-499 and the unsubstituted analog (Compound 4) was performed at 5-fold above the IC₅₀ determined for the open state (10 μ M and 1 μ M concentrations, respectively). Fractional current was determined from the tail current elicited after the first pulse. Control = $I_{\text{Last pulse}}$ $I_{1\text{st pulse}}$; 1st pulse = $I_{1\text{st pulse+Drug}}/I_{\text{Last pulse-Drug}}$ (n = 2-3; mean \pm SEM; *P < 0.05). (B) Evaluation of closed-channel block for the WT hERG channel by the unsubstituted analog (Compound 4) was performed at 5-fold above the IC₅₀ for the open state (25 nM). Fractional current was determined as described above (n = 2-3). Steady-state block for Compound 4 was confirmed on the same cell from the last pulse following activation for 5 s at 0 mV using the protocol described in Fig. 3 (*Last Pulse). (C) Model of drug access to the pore of hERG. MK-499 gains access to the pore of WT hERG in the open and inactivated states, but not the closed state. For the F656A hERG mutant, the smaller unsubstituted analog (Compound 4) can block the channel in the closed state, but not the larger parent compound, MK-499.

- narrowest region of the hERG channel in the closed state. Based on 356
- the maximal distance across Compound 4 (3.0 Å), the backbone $C\alpha$ 357 358 $-C\alpha$ distance across this region of the pore is likely in the range of
- 359 6 Å in the mutant channel.

360 4. Discussion

361 A variety of studies have identified the S6 residue F656 in hERG 362 as a critical component of drug binding interactions within the

pore of hERG. Although the F656A mutation has an effect on accelerating the inactivation of hERG, it has been demonstrated that the position of this aromatic residue along the S6 helix correlates with its effect on drug binding, and is not due to the effects on inactivation properties [33]. Additionally, Fernandez et al. have shown a good correlation between the approximate 2D van der Waals hydrophobic surface area of the residue at position 656 in hERG and the potency of MK-499, cisapride and terfenadine [34]. 370 Consistent with these observations, our results suggest that the 371

372

ARTICLE IN PRESS

J. Karczewski et al./Biochemical Pharmacology xxx (2009) xxx-xxx

effect of the F656A mutation on drug binding is primarily due to steric and/or energetic factors. The F656A mutation had been shown to significantly reduce the affinity of several bEPC inter-

steric and/or energetic factors. The F656A mutation had been
shown to significantly reduce the affinity of several hERG
antagonists potentially due to a key hydrophobic or cation-pi
interaction with these molecules, particularly MK-499 [8,27].

377 Although it was initially expected that the potency of all MK-378 499 analogs would be similarly affected, such is not the case. Subtle 379 differences amongst these analogs can dramatically affect the fold 380 difference in potency brought about by the F656A mutation. Since 381 the loss of interactions with F656 would likely be compensated for 382 by general hydrophobic interactions between the tetrahydro-383 naphthalene ring and the S6 helix, we focused our attention on the 384 potential interactions with the hydroxyl group at the 4-pyran 385 position in MK-499. Previous studies recognized the importance of 386 S624 in the binding of MK-499 to the channel and characterized 387 the residue as defining the pocket in which the methanesulfone is 388 bound [8]. The results of our study highlight a likely hydrogen 389 bonding interaction between these inhibitors and the sidechain of 390 Ser624 as well. These data help to further define the structural 391 requirements for binding to the hERG channel and in part explain 392 the pharmacological promiscuity of this channel.

393 The identification of F656 as a key residue involved in drug 394 trapping within the hERG pore suggests that it may play an 395 additional role in regulating accessibility during channel gating. As 396 the channel is cycled between the open, inactivated and closed 397 states to obtain steady-state block, many compounds, including 398 the methanesulfonanilides, become trapped and subsequently 399 become very difficult to wash-off. This might be due to the slow 400 rate of drug unbinding compared to the pulse-cycle rate, and/or to 401 high-affinity interactions between the drug and S6 residues which 402 alter open-channel gating.

403 Based on sequence alignment and a homology model with KcsA, 404 F656 in hERG would be equivalent to Thr107 in KcsA located just 405 below the conserved glycine "gating hinge" identified in the 406 structure of the MthK channel [35]. This is also one of the 407 narrowest regions of the pore in the structure of KcsA, which is 408 likely representative of the closed state [13]. Results from our 409 studies on drug accessibility in the inactivated and closed states of 410 hERG also suggest that F656 is localized in a narrow region of the 411 channel, and can act as a physical barrier from the intracellular 412 aspect of the pore. This may partially explain some of the features 413 of drug trapping observed in hERG since F656 may also act to 414 impede drug egress from the channel. Finally, accessibility of the 415 pore of F656A hERG to the small, unsubstituted analog in the 416 closed-state, but not to MK-499 or larger analogs, provides 417 additional evidence that this residue likely sets the minimal 418 diameter of the pore in the closed state.

419 Although determining the crystallographic structure of hERG 420 with an inhibitor bound within the pore could validate the 421 interactions that constitute the drug-binding site for this channel, a 422 broader understanding of the molecular landscape which renders 423 it so susceptible to a variety of small molecules may be best 424 understood using techniques which can characterize the channel 425 in its functional state. By applying high-throughput methods to 426 analyze the structure-function relationships with closely related 427 small molecules, a more detailed molecular map of the drug 428 binding site could be rapidly ascertained and probable atomic 429 interactions identified. This approach is similar to that used for 430 mapping toxin binding sites to the extracellular surface of voltage-431 dependent K⁺ channels, and could complement and extend 432 important insights from electrophysiological studies [36-38].

Utilizing this methodology for the hERG K⁺ channel, we have
established an initial model to account for the differential
sensitivities of related compounds to molecular perturbations
within the methanesulfonanilide binding site. By expanding our
study to investigate the impact of mutations near the selectivity

filter and along the length of the S6 helix, we hope to develop a438more comprehensive and detailed map of the drug-channel439interaction surface. A pharmacophore model based upon these and440other data could provide an improved means for facilitating early441drug development by the rapid, *in silico* identification of442compounds that may cause QT prolongation due to inhibition of443the hERG channel.444

Acknowledgements

We would like to thank Dr. Jason Elliott for synthesis of key
compounds used in this study, as well as Drs. Joseph J. Lynch, Maria
L. Garcia, Christopher J. Dinsmore and B. Wesley Trotter for their
helpful suggestions and comments on the manuscript.446
447
448

References

- Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92– 5.
- [2] Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299–307.
- [3] Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795–803.
- [4] Wymore RS, Gintant GA, Wymore RT, Dixon JE, McKinnon D, Cohen IS. Tissue and species distribution of mRNA for the IKr-like K+ channel, erg. Circ Res 1997;80:261–8.
- [5] Zhou Z, Gong Q, Epstein ML, January CT. HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. J Biol Chem 1998;273:21061–6.
- [6] Pearlstein R, Vaz R, Rampe D. Understanding the structure–activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem 2003;46:2017–22.
- [7] Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem 2002;277:23587–95.
- [8] Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329– 33.
- [9] Scott CW, Wilkins DE, Trivedi S, Crankshaw DJ. A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry. Anal Biochem 2003;319:251–7.
- [10] Zhou Z, Gong Q, January CT. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J Biol Chem 1999;274:31123–6.
- [11] Thomas D, Kiehn J, Katus HA, Karle CA. Defective protein trafficking in hERGassociated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res 2003;60:235– 41.
- [12] Ficker E, Dennis AT, Wang L, Brown AM. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 2003;92:e87–100.
- [13] Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 1998;280:69–77.
- [14] Kearsley SK, Underwood DJ, Sheridan RP, Miller MD. Flexibases: a way to enhance the use of molecular docking methods. J Comput Aided Mol Des 1994;8:565–82.
- [15] Halgren TA. MMFF VI. MMFF94s option for energy minimization studies. J Comput Chem 1999;20:720–9.
- [16] Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, et al. MacroModel – an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 1990;11:440–67.
- [17] Terstappen GC. Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. Anal Biochem 1999;272:149–55.
- [18] Tang W, Kang J, Wu X, Rampe D, Wang L, Shen H, et al. Development and evaluation of high throughput functional assay methods for HERG potassium channel. J Biomol Screen 2001;6:325–31.
- [19] Hu W, Toral J, Cervoni P, Ziai MR, Sokol PT. Depolarization-induced 86Rb+ efflux in CHO cells expressing a recombinant potassium channel. J Pharmacol Toxicol Methods 1995;34:1–7.
- [20] Robertson B, Owen DG. Pharmacology of a cloned potassium channel from mouse brain (MK-1) expressed in CHO cells: effects of blockers and an 'inactivation peptide'. Br J Pharmacol 1993;109:725–35.
- [21] Kiss L, Bennett PB, Uebele VN, Koblan KS, Kane SA, Neagle B, et al. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol 2003;1:127–35.

514

9

445

450

451

452

453 454

455

456

457

458

459

460

J. Karczewski et al. / Biochemical Pharmacology xxx (2009) xxx-xxx

- [22] Cheng CS, Alderman D, Kwash J, Dessaint J, Patel R, Lescoe MK, et al. A highthroughput HERG potassium channel function assay: an old assay with a new look. Drug Dev Ind Pharm 2002;28:177-91.
- [23] Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996;385:77-80.
- [24] Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001;299:1007-12.
- [25] Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998;286:788–93.
- [26] Lynch Jr JJ, Wallace AA, Stupienski 3rd RF, Baskin EP, Beare CM, et al. Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]. Pharmacol Exp Ther 1994;269:541-54.
- [27] Lees-Miller JP, Duan Y, Teng GQ, Duff HJ. Molecular determinant of highaffinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 2000;57:367-74.
- 5166 5177 5188 519 5200 5211 5222 5233 5244 5255 5266 5277 5288 5299 5300 5311 5322 5333 5344 5355 536 [28] Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003;139:887-98. 537
- [29] Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide 538 by closure of the HERG potassium channel activation gate. J Gen Physiol 539 2000;115:229-40.

- [30] Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC, et al. The low-potency, voltage-dependent HERG blocker propafenone-molecular determinants and drug trapping. Mol Pharmacol 2004;66:1201-12.
- Spector PS, Curran ME, Keating MT, Sanguinetti MC. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Openchannel block by methanesulfonanilides. Circ Res 1996;78:499-503.
- [32] Kiehn J, Lacerda AE, Wible B, Brown AM. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 1996;94:2572-9.
- [33] Chen J, Seebohm G, Sanguinetti MC. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci USA 2002;99:12461–6.
- [34] Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC. Physicochemical features of the HERG channel drug binding site. J Biol Chem 2004;279: 10120-7.
- [35] Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R. The open pore conformation of potassium channels. Nature 2002;417:523-6.
- [36] Hidalgo P. MacKinnon R. Revealing the architecture of a K+ channel pore through mutant cycles with a peptide inhibitor. Science 1995;268:307-10.
- Ranganathan R, Lewis JH, MacKinnon R. Spatial localization of the K+ channel selectivity filter by mutant cycle-based structure analysis. Neuron 1996;16:131-9.
- Imredy IP, MacKinnon R, Energetic and structural interactions between delta-[38] dendrotoxin and a voltage-gated potassium channel. J Mol Biol 2000;296: 1283-94.

565

Please cite this article in press as: Karczewski J, et al. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel. Biochem Pharmacol (2009), doi:10.1016/j.bcp.2009.02.011

10

515